Human Hyaluronidase · Amphadase, Hyaluronidase

What is Human Hyaluronidase?

Hyaluronidase is a recombinant human enzyme that hydrolyzes hyaluronic acid in connective tissue, temporarily decreasing viscosity and increasing permeability of the interstitial space. It is used as an adjuvant to enhance dispersion and absorption of subcutaneously administered fluids and drugs, and to improve resorption of radiopaque agents in urography.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Amphadase, Hyaluronidase, Hylenex Recombinant, Vitrase, RHUPH-20, Hylenex

Drug type

Recombinant protein

Targets

hyaluronic acid

Mechanism

Acts on hyaluronic acid

Pathways

connective tissue permeability, interstitial fluid absorption

Developer

Bausch And Lomb

In trials of

INO

FDA status

Approved as Amphadase, Hyaluronidase, Hylenex Recombinant (May 5, 2004), BLA021640 · FDA label

UNII

743QUY4VD8

✅ FDA-approved uses

• Subcutaneous fluid administration for achieving hydration (Hylenex Recombinant)
• Dispersion and absorption of other injected drugs (Hylenex Recombinant)
• Subcutaneous urography for improving resorption of radiopaque agents (Hylenex Recombinant)
• Subcutaneous fluid administration for achieving hydration (Amphadase)
• Dispersion and absorption of other injected drugs (Amphadase)
• Subcutaneous urography for improving resorption of radiopaque agents (Amphadase)

From the indications section of the FDA label (version of Nov 11, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Hylenex Recombinant (2024-11-11), indications
• FDA label Amphadase (2024-02-01), indications
• FDA label Hyaluronidase (2021-06-04), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT05293249

Updated Oct 3, 2026.